Scott Harris

Company: Altimmune

Job title: Chief Medical Officer

Seminars:

The Effects of GLP-1 Receptor Agonists on Lean Body Mass Loss & Associated Outcomes in Clinical Trials 2:00 pm - 2:30 pm

Navigating the rationale behind using GLP-1s to treat obesity, MASH and fatty liver disease Understanding the limitations of GLP-1 monotherapy and GLP-1/GIP dual agonists Strategies to increase the lean body mass retention of GLP-1 patientsRead more

day: Day One

Panel: Delving into Clinical Trial Design to Accurately Assess GLP-1s in Comorbidities of Obesity 3:00 pm - 3:30 pm

Exploring strategies for patient selection and stratification using baseline characteristics and specific comorbidities to assess differential treatment effects Considering the ethical implications of placebo arms to obtain reliable clinical data whilst ensuring patients receive required care Drawing on real world data to ensure adequate sample size and statistical testing to detect clinically meaningful differencesRead more

day: Day One